secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001104659-26-025293
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Oncology reports FY2025 net loss $183.1M; LOQTORZI revenue doubles to $40.8M
--------------------------------------------------------------------------------

- LOQTORZI net revenue $40.8M in 2025, more than double $19.1M in 2024; Q4 net revenue $12.4M up 11% QoQ.
- Total debt reduced 90% from $480M to $38.8M during 2024-2025; year-end cash $172.1M.
- FY2025 GAAP net loss $183.1M ($1.56 diluted) vs $215.4M loss in FY2024; non-GAAP loss $159.2M.
- Pipeline: tagmokitug (CCR8) trials in HNSCC, GI, ESCC, CRC; casdozokitug (IL-27) Phase 2 in 1L uHCC; data readouts in mid-2026.
- Equity financings: ~$7.9M net from Oct 2025 offering; ~$47.0M net from Feb 2026 public offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/0001104659-26-025293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-025293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer